Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex
30-01-2020
PTAB institutes IPRs on Sanofi patents
20-12-2017
nitpicker / Shutterstock.com
Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan over glargine (Lantus), a treatment for type 2 diabetes.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, SCOTUS, US Supreme Court, Lantus, patent, dispute, Mylan, glargine, type 2 diabetes
